Phase 2b, Randomized, 3-Month, Dose-Finding Study of Sepetaprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: The ANGEL Study

por Wirta, David L., Kuwayama, Yasuaki, Lu, Fenghe, Shao, Hui, Odani-Kawabata, Noriko
Publicado 2022

Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and...

por Aihara, Makoto, Lu, Fenghe, Kawata, Hisashi, Tanaka, Yuki, Yamamura, Kenzo, Odani-Kawabata, Noriko, Shams, Naveed K.
Publicado 2019

A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)

por Olander, Kenneth W., Sato, Michelle A., Abrams, Marc A., Jerkins, Gary W., Lu, Fenghe, Dinh, Phillip, Odani-Kawabata, Noriko, Chabi, Almira, Shams, Naveed K.
Publicado 2021